Daiichi Sankyo

News

Daiichi Sankyo has licensed European rights to GAIA's digital therapeutic for people with high cholesterol, currently in phase 3 testing.

Oncology

On the sidelines of JPM, Daiichi-Sankyo US CEO Ken Keller told pharmaphorum about the company's big year and its long-term strategy in ADCs.

News

Daiichi Sankyo has named John Tsai as its new global head of R&D, replacing Ken Takeshita, who is stepping down after five years in the role.

News

FDA has delivered a setback to AstraZeneca by rebuffing its new formulation of lupus therapy Saphnelo, which was approved in Europe last year.

News

EMA starts its review of first-line Enhertu in HER2+ breast cancer, which could dramatically increase the eligible patient population for the drug.

News

Daiichi Sankyo and AstraZeneca have filed their first marketing application for TROP2-targeting Datroway in triple-negative breast cancer.